Table 4.
Cancer Type. | Cellular Source | Vesicular Cargo | The Main Result | Refs. |
---|---|---|---|---|
Prostate cancer | DU145 | PGE2 | Triggered the expression of CD73 and then CD39 on DCs, resulting in inhibition of TNFα- and IL-12-production via an ATP-dependent manner | [156] |
NSCLC | Blood samples from NSCLC patients | Galectin-9 and Tim-3 | Interacted with TIM-3 on DCs | [157] |
Renal cancer | CD105+ CSCs CD105− TCs |
HLA-G | Disrupted maturation of DCs and T-cell immune responses | [133] |
Glioblastoma | CSF samples from glioma patients GL261 U87MG U118 MG |
Galectin-9 | Inhibited antigen recognition, processing, and presentation by interacting with TIM-3 on DCs | [142] |
Ascites of glioma patients | PD-L1 | Impaired DCs maturation via formation of immunosuppressive monocytes | [77] | |
Blood samples from glioma patients GSC20 GSC267 GSC17 MEC-1 |
Vesicular cargo | Skewed monocytes toward an immune suppressive phenotype and induced programmed PD-L1 expression on monocytes through STAT3 phosphorylation and TLR7-dependent manner | [33,158] | |
Melanoma | SKMEL28 A375 C32TG |
S100, A8/A9 | Inhibited DCs maturation and reduced expression of CD83, CD86, Th1 polarizing chemokines (such as Flt3L, IL-15), and migration chemokines (MIP-1α and MIP-1β) | [150] |
lymphatic fluid sample of melanoma patients ATCC |
S100A9 | Inhibited DCs maturation and prepared metastatic niche in lymph nodes | [159] | |
B16-F0 | TGF-β1 | Increased mRNA levels of IL-4 and TGF-β1 which inhibited DCs’ maturation | [160] | |
Blood samples from melanoma patients B16-F0 |
HSP72 and HSP105 | Induced secretion of IL-6 from DCs via TLR4- and TLR2-dependent manner activating STAT3-dependent MMP 9 activity | [161] | |
lymphocytic leukemia | Blood samples from CLL patients | S100A8/A9 | CD83, CD86, IL-12, and IL-15 expressions were all downregulated via activating the NFκB pathway | [162,163] |
lung carcinoma | LLC | PD-L1 | Myeloid precursor cells were unable to differentiate into CD11c+ DCs in the presence of vesicular PD-L1 and resulted in DCs death | [152] |
LLC A549 |
MALAT1 | Inhibited DC function and T-cell proliferation and increased DC autophagy via AKT/mTOR Pathway | [151] |
|
Breast cancer | MDA-MB-231 TS/A |
Vesicular cargo | Inhibited the development of myeloid precursor cells into DCs by increasing IL-6 production and reducing CD83 and CD86 expression | [149] |
4T1 | PD-L1 | Myeloid precursor cells were unable to differentiate into CD11c+ DCs in the presence of vesicular PD-L1 and resulted in DC death | [152] | |
Blood samples from melanoma patients 4T1 |
HSP72 and HSP105 | Promoted DCs to IL-6 secretion in a TLR2- and TLR4-dependent manner which activated STAT3-dependent MMP 9 activity | [161] |